Current Role of Dacomitinib in Head and Neck Cancer.

Eliçin, Olgun; Ozsahin, Mahmut (2016). Current Role of Dacomitinib in Head and Neck Cancer. Expert opinion on investigational drugs, 25(6), pp. 735-742. Informa Healthcare 10.1080/13543784.2016.1177022

[img] Text
2016 - Elicin, Ozsahin - Current Role of Dacomitinib in Head and Neck Cancer(2).pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (951kB) | Request a copy

INTRODUCTION Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal antibody cetuximab is the only approved therapy for curative and recurrent/metastatic patients. Other EGFR-targeting drugs either failed in the clinical trials or are still in the early phases of drug development and research. AREAS COVERED In this article, previously published data and ongoing studies regarding dacomitinib, a second-generation irreversible TKI, for the treatment of HNSCC are presented and discussed. EXPERT OPINION The current body of evidence is not mature enough to indicate the use of dacomitinib for the treatment of HNSCC in curative or in recurrent/metastatic settings. Phase II data suggest the potential of improved outcome in selected recurrent/metastatic HNSCC based on several biomarkers, which need to be evaluated in randomized phase III trials. Meanwhile, an ongoing phase I study is investigating dacomitinib's optimal dosing combined with and without cisplatin in the curative concomitant chemoradiotherapy setting.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Eliçin, Olgun

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1354-3784

Publisher:

Informa Healthcare

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

11 Apr 2017 08:47

Last Modified:

16 Sep 2017 01:20

Publisher DOI:

10.1080/13543784.2016.1177022

PubMed ID:

27070370

Uncontrolled Keywords:

Dacomitinib; epidermal growth factor; head and neck cancer; metastatic; radiotherapy; recurrent; squamous cell carcinoma; tyrosine kinase inhibitor

BORIS DOI:

10.7892/boris.92810

URI:

https://boris.unibe.ch/id/eprint/92810

Actions (login required)

Edit item Edit item
Provide Feedback